Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
Monoclonal Gammopathy of Undetermined Significancer (MGUS) is a blood disorder, not cancer with a higher-risk of bone damage/fractures- While conventional oncology considers all forms of pre-Myeloma to
Continue reading“A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent
Continue reading“We report nine cases of arthritis/joint pain associated with a monoclonal gammapathy of undermined significance (MGUS). Joint involvement was noted simultaneously or after the diagnosis of monoclonal
Continue reading“Conclusion: The median survival rate of study patients with MGUS was only slightly shorter than that of a comparable US population.” Hi David- My husband is 59. He was diagnosed with Multiple
Continue reading“For the 4% of people (MM) who are diagnosed at an early stage, the 5-year survival rate is over 77%. If the cancer has spread to a distant part of the body, the 5-year survival rate is over 54%.
Continue readingSmoldering multiple myeloma with an increasingly abnormal serum free light chain (FLC) ratio is associated with a higher risk for progression to active multiple myeloma Hi David- I was diagnosed with with
Continue readingMGUS is an asymptomatic blood disorder estimated to affect more than 3% of Caucasians over the age of 50 and more than twice that number of African Americans over the age of 50. Many newly-diagnosed
Continue readingWhat is the difference between a Single Plasmacytoma of bone (SBP) and Multiple Myeloma(MM)? A diagnosis of a single plasmacytoma of bone (SPB), smoldering multiple myeloma (SMM) or monoclonal gammopathy
Continue readingThe most common of these is solitary plasmacytoma of bone (SPB), accounting for 3–5% of all plasma cell malignancies. Prognostic Nomogram for Predicting Overall Survival of Solitary Bone Plasmacytoma
Continue readingSmoldering multiple myeloma is an intermediate stage between MGUS and myeloma and is associated with a higher risk of progression of approximately 10% year. Smoldering Multiple Myeloma (SMM) is a term
Continue reading“SMM is distinct from monoclonal gammopathy of undetermined significance (MGUS) due to a higher risk of progression to active MM disease. For patients at high-risk of progressing from SMM…” No.
Continue reading“…enabled detection of MGUS in 5.1% of the members of the community tested in the Olmsted County screening study cohort in the age group of 50 years or older.” According to the research
Continue reading